{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T16:58:01Z","timestamp":1784653081171,"version":"3.55.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.cld.2025.09.005","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T22:14:52Z","timestamp":1761257692000},"page":"71-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Acute Alcoholic Hepatitis"],"prefix":"10.1016","volume":"30","author":[{"given":"Stephanie","family":"Rutledge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Robert S.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.cld.2025.09.005_bib1","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1111\/acer.13108","article-title":"Diagnosis and treatment of alcoholic hepatitis: a systematic review","volume":"40","author":"Singal","year":"2016","journal-title":"Alcohol Clin Exp Res"},{"issue":"10","key":"10.1016\/j.cld.2025.09.005_bib2","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.2013.276300","article-title":"Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial","volume":"310","author":"Mathurin","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.cld.2025.09.005_bib3","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1053\/j.gastro.2009.04.062","article-title":"Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor","volume":"137","author":"Louvet","year":"2009","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2025.09.005_bib4","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrgastro.2015.35","article-title":"Alcoholic liver disease: mechanisms of injury and targeted treatment","volume":"12","author":"Louvet","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2025.09.005_bib5","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/MCG.0000000000000161","article-title":"Research ftT, Consortium EAHT. Trends in alcoholic hepatitis-related hospitalizations, financial burden, and mortality in the United States","volume":"49","author":"Jinjuvadia","year":"2015","journal-title":"J Clin Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2025.09.005_bib6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/ADM.0000000000000767","article-title":"Alcohol consumption in response to the COVID-19 pandemic in the United States","volume":"15","author":"Barbosa","year":"2021","journal-title":"J Addiction Med"},{"issue":"6","key":"10.1016\/j.cld.2025.09.005_bib7","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1002\/hep.32067","article-title":"Impact of COVID-19 pandemic on liver transplantation and alcohol-associated liver disease in the USA","volume":"74","author":"Cholankeril","year":"2021","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2025.09.005_bib8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/alcalc\/agab047","article-title":"Inter-hospital escalation-of-care referrals for severe alcohol-related liver disease with recent drinking during the COVID-19 Pandemic","volume":"57","author":"Chen","year":"2022","journal-title":"Alcohol"},{"issue":"3","key":"10.1016\/j.cld.2025.09.005_bib9","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/hep.31307","article-title":"COVID-19 hangover: a rising tide of alcohol use disorder and alcohol-associated liver disease","volume":"72","author":"Da","year":"2021","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.cld.2025.09.005_bib10","doi-asserted-by":"crossref","first-page":"e2118713","DOI":"10.1001\/jamanetworkopen.2021.18713","article-title":"Trends in liver transplantation for acute alcohol-associated hepatitis during the COVID-19 Pandemic in the US","volume":"4","author":"Bittermann","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"17","key":"10.1016\/j.cld.2025.09.005_bib11","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1001\/jama.2022.4308","article-title":"Alcohol-related deaths during the COVID-19 pandemic","volume":"327","author":"White","year":"2022","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.cld.2025.09.005_bib12","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/ajt.16143","article-title":"Liver transplantation for alcoholic hepatitis in the United States: excellent outcomes with profound temporal and geographic variation in frequency","volume":"21","author":"Cotter","year":"2021","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.cld.2025.09.005_bib13","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1053\/j.gastro.2018.05.011","article-title":"Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo-a meta-analysis of individual data from controlled trials","volume":"155","author":"Louvet","year":"2018","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2025.09.005_bib14","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jhep.2021.06.019","article-title":"Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: a worldwide study","volume":"75","author":"Arab","year":"2021","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2025.09.005_bib15","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jhep.2018.10.023","article-title":"Inflammatory pathways in alcoholic steatohepatitis","volume":"70","author":"Gao","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.09.005_bib16","series-title":"Cytokines in alcoholic liver disease","first-page":"205","author":"McClain","year":"1999"},{"issue":"2","key":"10.1016\/j.cld.2025.09.005_bib17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1530-0277.1990.tb00482.x","article-title":"Plasma tumor necrosis factor \u03b1 predicts decreased long-term survival in severe alcoholic hepatitis","volume":"14","author":"Felver","year":"1990","journal-title":"Alcohol Clin Exp Res"},{"issue":"12","key":"10.1016\/j.cld.2025.09.005_bib18","doi-asserted-by":"crossref","first-page":"917","DOI":"10.7326\/0003-4819-112-12-917","article-title":"Increased plasma tumor necrosis factor in severe alcoholic hepatitis","volume":"112","author":"Bird","year":"1990","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.cld.2025.09.005_bib19","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/hep.20206","article-title":"A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis","volume":"39","author":"Naveau","year":"2004","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2025.09.005_bib20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1572-0241.2004.04034.x","article-title":"A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis","volume":"99","author":"Menon","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2025.09.005_bib21","doi-asserted-by":"crossref","first-page":"G387","DOI":"10.1152\/ajpgi.1998.275.3.G387","article-title":"TNF-induced liver injury","volume":"275","author":"Bradham","year":"1998","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"1","key":"10.1016\/j.cld.2025.09.005_bib22","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/hep.30866","article-title":"Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases","volume":"71","author":"Crabb","year":"2020","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.cld.2025.09.005_bib23","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/liv.13430","article-title":"Interleukin-1 inhibition facilitates recovery from liver injury and promotes regeneration of hepatocytes in alcoholic hepatitis in mice","volume":"37","author":"Iracheta-Vellve","year":"2017","journal-title":"Liver Int"},{"issue":"10","key":"10.1016\/j.cld.2025.09.005_bib24","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1172\/JCI60777","article-title":"IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice","volume":"122","author":"Petrasek","year":"2012","journal-title":"J Clin Investig"},{"issue":"4","key":"10.1016\/j.cld.2025.09.005_bib25","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/hep.32478","article-title":"IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis","volume":"76","author":"Szabo","year":"2022","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2025.09.005_bib26","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2024.01.031","article-title":"Randomized trial of anakinra plus zinc vs. prednisone for severe alcohol-associated hepatitis","volume":"80","author":"Gawrieh","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.09.005_bib27","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0168-8278(22)00480-9","article-title":"Il-1beta signal inhibition in acute alcoholic hepatitis: a multicentre, randomised, double-blind, placebo-controlled phase 2 trial of canakinumab therapy (ISAIAH)","volume":"77","author":"Vergis","year":"2022","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2025.09.005_bib28","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1053\/j.gastro.2014.06.043","article-title":"Roles for chemokines in liver disease","volume":"147","author":"Marra","year":"2014","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.cld.2025.09.005_bib29","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1136\/gutjnl-2013-306098","article-title":"CCL20 mediates lipopolysaccharide induced liver injury and is a potential driver of inflammation and fibrosis in alcoholic hepatitis","volume":"63","author":"Silvia","year":"2014","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.cld.2025.09.005_bib30","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/hep.30249","article-title":"Pharmacological Inhibition of CCR2\/5 signaling prevents and reverses alcohol-induced liver damage, steatosis, and inflammation in mice","volume":"69","author":"Ambade","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.09.005_bib31","series-title":"Selonsertib in combination with prednisolone for the treatment of severe alcoholic hepatitis: a phase 2 randomized controlled trial","first-page":"8A","author":"Mathurin","year":"2018"},{"issue":"4","key":"10.1016\/j.cld.2025.09.005_bib32","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11883-015-0500-2","article-title":"FXR agonists as therapeutic agents for non-alcoholic fatty liver disease","volume":"17","author":"Carr","year":"2015","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"10.1016\/j.cld.2025.09.005_bib33","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/apt.15030","article-title":"Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3\/7 activation in subjects with non-alcoholic fatty liver disease","volume":"49","author":"Shiffman","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.cld.2025.09.005_bib34","doi-asserted-by":"crossref","first-page":"E577","DOI":"10.1152\/ajpendo.00406.2023","article-title":"Larsucosterol: endogenous epigenetic regulator for treating chronic and acute liver diseases","volume":"326","author":"Wang","year":"2024","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.cld.2025.09.005_bib35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.14309\/ajg.0000000000002275","article-title":"Safety, pharmacokinetics, and efficacy signals of larsucosterol (DUR-928) in Alcohol-Associated Hepatitis","volume":"119","author":"Hassanein","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2025.09.005_bib36","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400243","article-title":"Larsucosterol for the treatment of alcohol-associated hepatitis","volume":"4","author":"Shiffman","year":"2025","journal-title":"NEJM Evidence"},{"issue":"10","key":"10.1016\/j.cld.2025.09.005_bib38","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/j.1478-3231.2011.02604.x","article-title":"Antioxidants as therapeutic agents for liver disease","volume":"31","author":"Singal","year":"2011","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.cld.2025.09.005_bib39","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1478-3231.2006.01245.x","article-title":"Relationship between oxidative stress levels and activation state on a hepatic stellate cell line","volume":"26","author":"Guimar\u00e3es","year":"2006","journal-title":"Liver Int"},{"issue":"8","key":"10.1016\/j.cld.2025.09.005_bib40","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0891-5849(00)00380-4","article-title":"The reaction of superoxide radical with N-acetylcysteine","volume":"29","author":"Benrahmoune","year":"2000","journal-title":"Free Radic Biol Med"},{"issue":"19","key":"10.1016\/j.cld.2025.09.005_bib41","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1101214","article-title":"Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis","volume":"365","author":"Nguyen-Khac","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.cld.2025.09.005_bib42","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1007\/s10620-020-06142-4","article-title":"A combination of n-acetylcysteine and prednisone has no benefit over prednisone alone in severe alcoholic hepatitis: a retrospective analysis","volume":"65","author":"Amjad","year":"2020","journal-title":"Dig Dis Sci"},{"issue":"10","key":"10.1016\/j.cld.2025.09.005_bib43","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.cgh.2018.01.040","article-title":"Efficacy of granulocyte colony-stimulating factor and N-acetylcysteine therapies in patients with severe alcoholic hepatitis","volume":"16","author":"Singh","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2025.09.005_bib44","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jhep.2010.05.030","article-title":"Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial","volume":"53","author":"Moreno","year":"2010","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2025.09.005_bib45","first-page":"17","article-title":"Effects of Metadoxine on cellular status of glutathione and of enzymatic defence system following acute ethanol intoxication in rats","volume":"22","author":"Calabrese","year":"1996","journal-title":"Drugs Exp Clin Res"},{"issue":"3","key":"10.1016\/j.cld.2025.09.005_bib46","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/039463200301600304","article-title":"Metadoxine in the treatment of acute and chronic alcoholism: a review","volume":"16","author":"Addolorato","year":"2003","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"3","key":"10.1016\/j.cld.2025.09.005_bib47","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1665-2681(19)30863-4","article-title":"Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis","volume":"13","author":"Higuera-de la Tijera","year":"2014","journal-title":"Ann Hepatol"},{"issue":"16","key":"10.1016\/j.cld.2025.09.005_bib48","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.3748\/wjg.v21.i16.4975","article-title":"Metadoxine improves the three-and six-month survival rates in patients with severe alcoholic hepatitis","volume":"21","author":"Higuera-de la Tijera","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cld.2025.09.005_bib49","article-title":"S-adenosyl-L-methionine for alcoholic liver diseases","volume":"4","author":"Rambaldi","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.cld.2025.09.005_bib50","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0168-8278(03)00476-8","article-title":"A randomized placebo controlled trial of vitamin E for alcoholic hepatitis","volume":"40","author":"Mezey","year":"2004","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2025.09.005_bib51","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4103\/2231-0738.184582","article-title":"Efficacy of Vitamin E supplementation in patients with alcoholic liver disease: an open-label, prospective, randomized comparative study","volume":"6","author":"Kolasani","year":"2016","journal-title":"Int J Nutr, Pharmacol, Neurol Dis"},{"issue":"4","key":"10.1016\/j.cld.2025.09.005_bib52","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jhep.2005.11.039","article-title":"Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis\u2014a randomised clinical trial","volume":"44","author":"Phillips","year":"2006","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2025.09.005_bib53","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jhep.2015.04.003","article-title":"Hepatic cell proliferation plays a pivotal role in the prognosis of alcoholic hepatitis","volume":"63","author":"Lanthier","year":"2015","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2025.09.005_bib54","doi-asserted-by":"crossref","first-page":"G1019","DOI":"10.1152\/ajpgi.00239.2006","article-title":"IL-22-mediated liver cell regeneration is abrogated by SOCS-1\/3 overexpression in vitro","volume":"292","author":"Brand","year":"2007","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"5","key":"10.1016\/j.cld.2025.09.005_bib55","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1053\/j.gastro.2014.01.018","article-title":"A histologic scoring system for prognosis of patients with alcoholic hepatitis","volume":"146","author":"Altamirano","year":"2014","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.cld.2025.09.005_bib56","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1136\/gutjnl-2014-308410","article-title":"Progenitor cell expansion and impaired hepatocyte regeneration in explanted livers from alcoholic hepatitis","volume":"64","author":"Dubuquoy","year":"2015","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.cld.2025.09.005_bib57","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41575-020-0342-4","article-title":"Liver regeneration: biological and pathological mechanisms and implications","volume":"18","author":"Michalopoulos","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2025.09.005_bib58","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/hep.22317","article-title":"Granulocyte-colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial","volume":"48","author":"Spahr","year":"2008","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2025.09.005_bib59","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1053\/j.gastro.2011.11.027","article-title":"Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure","volume":"142","author":"Garg","year":"2012","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.cld.2025.09.005_bib60","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/ajg.2014.154","article-title":"Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study","volume":"109","author":"Singh","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2025.09.005_bib61","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/hep.30516","article-title":"Efficacy of granulocyte colony-stimulating factor in the management of steroid-nonresponsive severe alcoholic hepatitis: a double-blind randomized controlled trial","volume":"70","author":"Shasthry","year":"2019","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2025.09.005_bib62","article-title":"Granulocyte colony-stimulating factor for alcoholic hepatitis: a systematic review and meta-analysis of randomised controlled trials","volume":"2","author":"Marot","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.cld.2025.09.005_bib63","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/jgh.12032","article-title":"Hepatoprotective and anti-fibrotic functions of interleukin-22: therapeutic potential for the treatment of alcoholic liver disease","volume":"28","author":"Kong","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2025.09.005_bib64","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/hep.31046","article-title":"An open-label, dose-escalation study to assess the safety and efficacy of IL-22 agonist F-652 in patients with alcohol-associated hepatitis","volume":"72","author":"Arab","year":"2020","journal-title":"Hepatology"},{"issue":"32","key":"10.1016\/j.cld.2025.09.005_bib65","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.3748\/wjg.v28.i32.4557","article-title":"Liver regeneration as treatment target for severe alcoholic hepatitis","volume":"28","author":"Virovic-Jukic","year":"2022","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2025.09.005_bib66","article-title":"New approaches or correction of genetic and metabolic diseases","volume":"7","author":"Vassilopoulos","year":"2003","journal-title":"Mol Ther"},{"issue":"7","key":"10.1016\/j.cld.2025.09.005_bib67","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1634\/stemcells.2005-0629","article-title":"Characterization and clinical application of human CD34+ stem\/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor","volume":"24","author":"Gordon","year":"2006","journal-title":"Stem Cell"},{"issue":"1","key":"10.1016\/j.cld.2025.09.005_bib68","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13287-019-1547-8","article-title":"Mesenchymal stem cells alleviate liver injury induced by chronic-binge ethanol feeding in mice via release of TSG6 and suppression of STAT3 activation","volume":"11","author":"Wan","year":"2020","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"10.1016\/j.cld.2025.09.005_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053719","article-title":"Autologous bone marrow mononuclear cell transplantation in patients with decompensated alcoholic liver disease: a randomized controlled trial","volume":"8","author":"Spahr","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.cld.2025.09.005_bib70","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.dld.2015.08.018","article-title":"Reinfusion of highly purified CD133+ bone marrow-derived stem\/progenitor cells in patients with end-stage liver disease: A phase I clinical trial","volume":"47","author":"Andreone","year":"2015","journal-title":"Dig Liver Dis"},{"issue":"6","key":"10.1016\/j.cld.2025.09.005_bib71","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/lt.24396","article-title":"Extracorporeal liver support devices for listed patients","volume":"22","author":"Lee","year":"2016","journal-title":"Liver Transplant"},{"issue":"3","key":"10.1016\/j.cld.2025.09.005_bib72","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1002\/hep.26185","article-title":"Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial","volume":"57","author":"Ba\u00f1ares","year":"2013","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2025.09.005_bib73","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1053\/j.gastro.2011.12.056","article-title":"Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure","volume":"142","author":"Kribben","year":"2012","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2025.09.005_bib74","doi-asserted-by":"crossref","DOI":"10.1186\/cc4985","article-title":"Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure","volume":"10","author":"Laleman","year":"2006","journal-title":"Crit Care"},{"issue":"3","key":"10.1016\/j.cld.2025.09.005_bib75","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/lt.24986","article-title":"Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: a multinational, prospective, controlled, randomized trial","volume":"24","author":"Thompson","year":"2018","journal-title":"Liver Transplant"},{"issue":"5","key":"10.1016\/j.cld.2025.09.005_bib76","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jhep.2013.12.019","article-title":"Altered profile of human gut microbiome is associated with cirrhosis and its complications","volume":"60","author":"Bajaj","year":"2014","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.cld.2025.09.005_bib77","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1111\/acer.13498","article-title":"Continued alcohol misuse in human cirrhosis is associated with an impaired gut\u2013liver axis","volume":"41","author":"Bajaj","year":"2017","journal-title":"Alcohol Clin Exp Res"},{"issue":"5","key":"10.1016\/j.cld.2025.09.005_bib78","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/gutjnl-2015-310585","article-title":"Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease","volume":"65","author":"Llopis","year":"2016","journal-title":"Gut"},{"issue":"7783","key":"10.1016\/j.cld.2025.09.005_bib79","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41586-019-1742-x","article-title":"Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease","volume":"575","author":"Duan","year":"2019","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.cld.2025.09.005_bib80","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1136\/gutjnl-2016-313432","article-title":"Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease","volume":"67","author":"Grander","year":"2018","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.cld.2025.09.005_bib81","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1136\/gutjnl-2016-313170","article-title":"Fungal dysbiosis in cirrhosis","volume":"67","author":"Bajaj","year":"2018","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.cld.2025.09.005_bib82","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1172\/JCI90562","article-title":"Intestinal fungi contribute to development of alcoholic liver disease","volume":"127","author":"Yang","year":"2017","journal-title":"J Clin Investig"},{"issue":"8","key":"10.1016\/j.cld.2025.09.005_bib83","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.alcohol.2008.08.006","article-title":"Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study","volume":"42","author":"Kirpich","year":"2008","journal-title":"Alcohol"},{"issue":"11","key":"10.1016\/j.cld.2025.09.005_bib84","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1097\/MEG.0000000000000458","article-title":"Effects of probiotics (cultured Lactobacillus subtilis\/Streptococcus faecium) in the treatment of alcoholic hepatitis: randomized-controlled multicenter study","volume":"27","author":"Han","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2025.09.005_bib85","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.14309\/ajg.0000000000002283","article-title":"The beneficial effects of lactobacillus GG therapy on liver and drinking assessments in patients with moderate alcohol-associated hepatitis","volume":"118","author":"Vatsalya","year":"2023","journal-title":"Official J Am Coll Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2025.09.005_bib86","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.cgh.2016.10.029","article-title":"Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: a pilot study","volume":"15","author":"Philips","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.09.005_bib87","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s12664-018-0859-4","article-title":"Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis","volume":"37","author":"Philips","year":"2018","journal-title":"Indian J Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2025.09.005_bib88","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/hep.31496","article-title":"A randomized clinical trial of fecal microbiota transplant for alcohol use disorder","volume":"73","author":"Bajaj","year":"2021","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2025.09.005_bib89","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jceh.2022.01.001","article-title":"Long-term outcomes of stool transplant in alcohol-associated hepatitis\u2014analysis of clinical outcomes, relapse, gut microbiota and comparisons with standard care","volume":"12","author":"Philips","year":"2022","journal-title":"J Clin Exp Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2025.09.005_bib90","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s12072-022-10312-z","article-title":"Fecal microbiota transplantation in alcohol-associated acute-on-chronic liver failure: an open-label clinical trial","volume":"16","author":"Sharma","year":"2022","journal-title":"Hepatol Int"},{"key":"10.1016\/j.cld.2025.09.005_bib91","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3389\/fmed.2020.00448","article-title":"Non-alcoholic fatty liver disease and alcohol-related liver disease: two intertwined entities","volume":"7","author":"Idalsoaga","year":"2020","journal-title":"Front Med"},{"issue":"5","key":"10.1016\/j.cld.2025.09.005_bib92","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1053\/j.gastro.2011.09.002","article-title":"Alcoholic liver disease: pathogenesis and new therapeutic targets","volume":"141","author":"Gao","year":"2011","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2025.09.005_bib93","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/gutjnl-2011-301239","article-title":"Genetic determinants of alcoholic liver disease","volume":"61","author":"Stickel","year":"2012","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.cld.2025.09.005_bib94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-21939-0","article-title":"Evaluation of polygenic determinants of non-alcoholic fatty liver disease (NAFLD) by a candidate genes resequencing strategy","volume":"8","author":"Di Costanzo","year":"2018","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.cld.2025.09.005_bib95","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/ajg.2015.137","article-title":"PNPLA3 gene polymorphism is associated with predisposition to and severity of alcoholic liver disease","volume":"110","author":"Salameh","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.cld.2025.09.005_bib96","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ng.3417","article-title":"A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis","volume":"47","author":"Buch","year":"2015","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.cld.2025.09.005_bib97","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1194\/jlr.M600185-JLR200","article-title":"Characterization of the human patatin-like phospholipase familys","volume":"47","author":"Wilson","year":"2006","journal-title":"J Lipid Res"},{"issue":"12","key":"10.1016\/j.cld.2025.09.005_bib98","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"issue":"12","key":"10.1016\/j.cld.2025.09.005_bib99","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A protein-truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.cld.2025.09.005_bib100","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/liv.14495","article-title":"Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non-alcoholic fatty liver disease","volume":"40","author":"Seko","year":"2020","journal-title":"Liver Int"},{"issue":"7","key":"10.1016\/j.cld.2025.09.005_bib101","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3390\/jpm11070619","article-title":"Is HSD17B13 genetic variant a protector for liver dysfunction? future perspective as a potential therapeutic target","volume":"11","author":"Motomura","year":"2021","journal-title":"J Personalized Med"},{"issue":"36","key":"10.1016\/j.cld.2025.09.005_bib102","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.3748\/wjg.v26.i36.5474","article-title":"Pediatric non-alcoholic fatty liver disease and kidney function: effect of HSD17B13 variant","volume":"26","author":"Di Sessa","year":"2020","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cld.2025.09.005_bib103","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41575-018-0099-1","article-title":"Alcohol, liver disease and the gut microbiota","volume":"16","author":"Bajaj","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.09.005_bib104","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.913842","article-title":"Gut microbiota-modulating agents in alcoholic liver disease: links between host metabolism and gut microbiota. Review","author":"Jung","year":"2022","journal-title":"Front Med"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326125000868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326125000868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T11:57:53Z","timestamp":1766145473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326125000868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":103,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1089326125000868"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2025.09.005","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute Alcoholic Hepatitis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2025.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}